Medicure Inc (MPH : TSX-V)
Common Stock
$1.11
CAD
-0.05 (-4.31%)
Last updated: 2026-06-02
MPH
Medicure Inc
WealthAwesomePerformance
1 Day
-4.31%
1 Week
+0.91%
1 Month
+5.71%
YTD
-2.63%
Key Statistics
Market Cap
$12.11M
52W High
$1.43
52W Low
$0.85
P/E Ratio
-
50 Day MA
$1.16
200 Day MA
$1.15
Beta
0.97
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/2/2026 | $1.11 | $1.11 | $1.11 | $1.11 | $1.11 | 5,000 |
| 6/1/2026 | $1.16 | $1.16 | $1.16 | $1.16 | $1.16 | 3,081 |
| 5/27/2026 | $1.11 | $1.11 | $1.11 | $1.11 | $1.11 | 5,000 |
| 5/25/2026 | $1.10 | $1.10 | $1.10 | $1.10 | $1.10 | 0 |
| 5/22/2026 | $1.10 | $1.10 | $1.10 | $1.10 | $1.10 | 7,066 |
| 5/21/2026 | $1.10 | $1.10 | $1.10 | $1.10 | $1.10 | 5,400 |
| 5/20/2026 | $1.19 | $1.20 | $1.19 | $1.20 | $1.20 | 2,000 |
| 5/19/2026 | $1.15 | $1.15 | $1.10 | $1.10 | $1.10 | 700 |
| 5/14/2026 | $1.19 | $1.19 | $1.19 | $1.19 | $1.19 | 1,000 |
| 5/13/2026 | $1.05 | $1.15 | $1.05 | $1.15 | $1.15 | 1,600 |
Analyst Price Targets
Based on analyst covering MPH
Wall Street analysts forecast MPH stock price to rise 152.3% over the next 12 months.
Consensus
No RatingAvg. Target
C$2.80
+152.3% Upside
Current Price
C$1.11
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MPH's historical volatility
30-Day Vol
156.8%
Annualized
90-Day Vol
157.1%
Annualized
Trend (90d)
-49.9%
Annualized drift
90d Mean
C$0.93
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.05 | C$0.61 โ C$1.80 |
| 60 trading days | C$0.99 | C$0.46 โ C$2.12 |
| 90 trading days | C$0.93 | C$0.36 โ C$2.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Financials
- Revenue (TTM)
- $31.32M
- EBITDA
- $-4.88M
- Profit Margin
- -21.74%
- ROE (TTM)
- -41.57%
- EPS (Diluted)
- -0.65
- Book Value
- 1.24
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MPH
Articles Featuring MPH.V
Latest articles and analysis covering MPH.V
